# US 2008/0306159 A1 · Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306159 A1
- Document ID: US20080306159A1
- Status: Published application
- Kind: A1
- Application number: 12/133,228
- Filed: 2008-06-04
- Published: 2008-12-11
- Earliest claimed: 2007-06-05
- Inventors: F. Joseph Daugherty; John R. Palmer, JR.; Michael S. Tempesta
- Web page: https://patentgrep.com/patent/US20080306159A1

## CPC

- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/286: {Polysaccharides, e.g. gums; Cyclodextrin}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/16: Anti-Parkinson drugs
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.

## Claims

### Claim 1

A oral creatine formulation comprising:
creatine hydrochloride; and
polyethylene glycol,
wherein the creatine hydrochloride and polyethylene glycol are coated with an enteric coating.

### Claim 2 (depends on 1)

The creatine formulation of claim 1, wherein the polyethylene glycol has an average molecular weight of from 3150 to 3685.

### Claim 3 (depends on 1)

The creatine formulation of claim 1, wherein the polyethylene glycol has an average molecular weight of from 3600 to 4400.

### Claim 4 (depends on 1)

The creatine formulation of claim 1, wherein the polyethylene glycol has an average molecular weight of from 4400 to 4800

### Claim 5 (depends on 1)

The creatine formulation of claim 1, wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents.

### Claim 6 (depends on 2)

The creatine formulation of claim 2, wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents.

### Claim 7 (depends on 3)

The creatine formulation of claim 3, wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents.

### Claim 8 (depends on 4)

The creatine formulation of claim 4 wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents.

### Claim 9 (depends on 1)

The creatine formulation of claim 1, wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents.

### Claim 10 (depends on 2)

The creatine formulation of claim 2, wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents.

### Claim 11 (depends on 3)

The creatine formulation of claim 3, wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents.

### Claim 12 (depends on 4)

The creatine formulation of claim 4 wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents.

### Claim 13 (depends on 1)

The creatine formulation of claim 1, wherein the formulation after ingestion, is effective to relieve, minimize or prevent symptoms of Parkinson's disease.

### Claim 14 (depends on 1)

The creatine formulation of claim 1, wherein the formulation after ingestion, is effective to relieve, minimize or prevent symptoms of a muscle-wasting disease or condition.

### Claim 15

A method of supplementing a mammal's creatine stores comprising providing a mixture of polyethylene glycol and a soluble creatine coated with an enteric coating and ingesting the coated creatine formulation.

### Claim 16 (depends on 15)

The method of claim 15, wherein the polyethylene glycol has an average molecular weight of from 3150 to 3685.

### Claim 17 (depends on 15)

The method of claim 15, wherein from 0.1 to 20 grams of the soluble creatine are ingested per day.

### Claim 18 (depends on 15)

The method of claim 15, wherein from 0.5 to 2 grams of the soluble creatine are ingested per day.

### Claim 19

A method of minimizing symptoms of a muscle-wasting disease or condition comprising providing a mixture of polyethylene glycol and a soluble creatine coated with an enteric coating and ingesting the coated creatine formulation.

### Claim 20 (depends on 19)

The method of claim 19, wherein the polyethylene glycol has an average molecular weight of from 3150 to 3685.

### Claim 21 (depends on 19)

The method of claim 19, wherein from 0.1 to 10 grams of the soluble creatine are ingested per day.

### Claim 22 (depends on 19)

The method of claim 19, wherein from 10 to 20 grams of the soluble creatine are ingested per day.
